- 现金
- 222032 元
- 精华
- 285
- 帖子
- 67620
- 注册时间
- 2001-11-10
- 最后登录
- 2023-5-7
|
1楼
发表于 2004-9-12 04:52
Journal of Viral Hepatitis
Volume 11 Issue 5 Page 432 - September 2004
doi:10.1111/j.1365-2893.2004.00556.x
[B]Sustained response after a 2-year course of lamivudine treatment of
hepatitis B e antigen-negative chronic hepatitis B[/B]
S. K. Fung1,2, F. Wong1, M. Hussain2 and A. S. F. Lok2
Summary. Lamivudine has demonstrated efficacy for the treatment of hepatitis
B e antigen-negative chronic hepatitis B (e-CHB). However, treatment
withdrawal after 1 year has been associated with a high rate of relapse
while long-term treatment is associated with increasing risks of drug
resistance. We report our treatment experience of 50 Chinese-Canadian
patients with e-CHB. All patients received lamivudine for 2 years. Treatment
was withdrawn at month 24 in patients who had undetectable hepatitis B virus
(HBV) DNA by PCR and normal aminotransferases during the second year of
therapy. All patients had HBV genotype B or C. Biochemical response at
months 6, 12 and 24 was 74%, 71% and 66%, respectively. HBV DNA was
undetectable at months 6, 12 and 24 by hybrid capture and PCR assays in
100%, 92% and 86%; and 94%, 88% and 74% patients, respectively. The
cumulative rates of genotypic resistance (GR) after 1 and 2 years were 15%
and 25%, respectively. Four (44%) patients with GR experienced a hepatitis
flare. The probability of clinical and virological relapse 6, 12, and 18
months after treatment withdrawal were 12% and 30%, 18% and 50%, and 30% and
50%, respectively. Reinstitution of lamivudine resulted in prompt
virological and biochemical responses. Our study demonstrates that a
sustained response can be achieved after a 2-year course of lamivudine in a
subset of patients with e-CHB.
|
|